Alarice Cheng-Yi Lowe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alarice Cheng-Yi Lowe has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Yili Zhu
Department of Pathology Stanford University School of Medicine Palo Alto California USA
5 shared publications Grace M. Allard
Department of Pathology Stanford University School of Medicine Stanford California USA
4 shared publicationsAihui Wang
Department of Pathology Stanford University School of Medicine Stanford California USA
2 shared publications- Cecilia Gimenez
Department of Pathology Zucker School of Medicine at Hofstra/Northwell Manhasset New York USA
2 shared publications Christian A. Kunder
Department of Pathology Stanford University School of Medicine Palo Alto California USA
2 shared publications- Diane Libert
Department of Pathology, Stanford University School of Medicine, Stanford, California
2 shared publications
Latest Publications
- 7 March 2026
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 15 (4) , 288-296
Evaluation of low-cost portable microscopes for rapid on-site evaluation of fine-needle aspirates in a clinical environment
- 7 March 2026
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 15 (4) , 288-296
Evaluation of low-cost portable microscopes for rapid on-site evaluation of fine-needle aspirates in a clinical environment
- 19 November 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (12) , e70061
The feasibility of low‐cost portable microscopes as an alternative to standard microscopes for rapid on‐site evaluation of FNA
Background: The high cost of professional‐quality microscopes for pathology labs can create a barrier to the availability of diagnostic services, especially in resource‐constrained settings. Low‐cost portable microscopes (LCPMs) are popular for recreational use and widely available. To our knowledge, they have not been evaluated for use in rapid on‐site evaluation (ROSE). The aim of this study was to identify which LCPMs have the potential for clinical use. Methods: In this investigation, five LCPMs were evaluated by 18 pathology professionals to determine the adequacy of fine‐needle aspiration (FNA) biopsy readings using patient‐generated material. Participants were surveyed to systematically assess preferred and undesirable characteristics of LCPMs and to provide feedback on their use. Results: Most expressed that though LCPMs were not a comparable replacement for standard microscopes, they were a better option than nothing and could be helpful in instances with highly cellular and relatively flat slide preparations. Most participants believed that LCPMs could be used for ROSE in resource‐limited environments. Conclusions: Pathology professional evaluated LCPMs on simulated fine‐needle aspiration biopsy smear slides. The feedback they provided in this study suggests that LCPMs may be a feasible alternative to standard microscopes for ROSE in resource‐limited settings.
- 19 November 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (12) , e70061
The feasibility of low‐cost portable microscopes as an alternative to standard microscopes for rapid on‐site evaluation of FNA
Background: The high cost of professional‐quality microscopes for pathology labs can create a barrier to the availability of diagnostic services, especially in resource‐constrained settings. Low‐cost portable microscopes (LCPMs) are popular for recreational use and widely available. To our knowledge, they have not been evaluated for use in rapid on‐site evaluation (ROSE). The aim of this study was to identify which LCPMs have the potential for clinical use. Methods: In this investigation, five LCPMs were evaluated by 18 pathology professionals to determine the adequacy of fine‐needle aspiration (FNA) biopsy readings using patient‐generated material. Participants were surveyed to systematically assess preferred and undesirable characteristics of LCPMs and to provide feedback on their use. Results: Most expressed that though LCPMs were not a comparable replacement for standard microscopes, they were a better option than nothing and could be helpful in instances with highly cellular and relatively flat slide preparations. Most participants believed that LCPMs could be used for ROSE in resource‐limited environments. Conclusions: Pathology professional evaluated LCPMs on simulated fine‐needle aspiration biopsy smear slides. The feedback they provided in this study suggests that LCPMs may be a feasible alternative to standard microscopes for ROSE in resource‐limited settings.
- 13 January 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (2) , e22931
Cytologic diagnosis of fumarate hydratase‐deficient renal cell carcinoma: A single‐institutional experience
Background: Fumarate hydratase‐deficient renal cell carcinoma (FHRCC) is an aggressive carcinoma that typically presents as advanced‐stage disease. Prompt recognition of FHRCC is critical for appropriate clinical care and genetic counseling for patients and family members. However, diagnosing FHRCC from cytology specimens is challenging, with limited characterization and no reports describing prospectively identified cases.Methods: Cytology fine‐needle aspiration (FNA) cases diagnosed as FHRCC were reviewed, including two prospectively identified cases.Results: Five cases of FHRCC diagnosed by FNA cytology were identified in five unique patients. The cytologic samples included four FNAs with core biopsy and one FNA with cell block. Biopsy sites included kidney (n = 1), chest wall (n = 1), omentum (n = 1), lung (n = 1), and cervical lymph node (n = 1). All cases demonstrated cytologically malignant epithelial cells characterized by enlarged, round nuclei with variable pleomorphism, irregular nuclear membranes, prominent nucleoli, and moderate‐to‐abundant amounts of cytoplasm. Perinucleolar halos characterized by chromatin margination and pallor around macronucleoli were seen in all cases. Cytologic features not previously described included cytoplasmic macrovacuoles and eosinophilic globules, cytophagocytosis, and floral groups. Papillary architecture was rarely present on aspirate smears. Cell block sections showed variable architectural patterns. By immunohistochemistry, FH was definitively lost in three of five cases (60%), and 2‐succinocysteine was positive in all 5 cases (100%).Conclusions: Cytologic specimens of FHRCC demonstrate salient cytomorphologic features that can support their initial diagnosis. Confirmatory immunohistochemical testing using a dual panel of fumarate hydratase and 2‐succinocysteine is recommended for the diagnosis in limited biopsy samples.
- 13 January 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (2) , e22931
Cytologic diagnosis of fumarate hydratase‐deficient renal cell carcinoma: A single‐institutional experience
Background: Fumarate hydratase‐deficient renal cell carcinoma (FHRCC) is an aggressive carcinoma that typically presents as advanced‐stage disease. Prompt recognition of FHRCC is critical for appropriate clinical care and genetic counseling for patients and family members. However, diagnosing FHRCC from cytology specimens is challenging, with limited characterization and no reports describing prospectively identified cases.Methods: Cytology fine‐needle aspiration (FNA) cases diagnosed as FHRCC were reviewed, including two prospectively identified cases.Results: Five cases of FHRCC diagnosed by FNA cytology were identified in five unique patients. The cytologic samples included four FNAs with core biopsy and one FNA with cell block. Biopsy sites included kidney (n = 1), chest wall (n = 1), omentum (n = 1), lung (n = 1), and cervical lymph node (n = 1). All cases demonstrated cytologically malignant epithelial cells characterized by enlarged, round nuclei with variable pleomorphism, irregular nuclear membranes, prominent nucleoli, and moderate‐to‐abundant amounts of cytoplasm. Perinucleolar halos characterized by chromatin margination and pallor around macronucleoli were seen in all cases. Cytologic features not previously described included cytoplasmic macrovacuoles and eosinophilic globules, cytophagocytosis, and floral groups. Papillary architecture was rarely present on aspirate smears. Cell block sections showed variable architectural patterns. By immunohistochemistry, FH was definitively lost in three of five cases (60%), and 2‐succinocysteine was positive in all 5 cases (100%).Conclusions: Cytologic specimens of FHRCC demonstrate salient cytomorphologic features that can support their initial diagnosis. Confirmatory immunohistochemical testing using a dual panel of fumarate hydratase and 2‐succinocysteine is recommended for the diagnosis in limited biopsy samples.
- 24 April 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (4) , 244-253
Science, Medicine, and Cytology: an educational program of the Diversity, Equity, and Inclusion Committee of the American Society of Cytopathology
- 24 April 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (4) , 244-253
Science, Medicine, and Cytology: an educational program of the Diversity, Equity, and Inclusion Committee of the American Society of Cytopathology
- 19 February 2024
- Published by Wiley in Cancer Cytopathology
- Vol. 132 (5) , 297-308
Detection of effusion tumor cells under different storage and processing conditions
Background: Circulating tumor cells (CTCs) shed into blood provide prognostic and/or predictive information. Previously, the authors established an assay to detect carcinoma cells from pleural fluid, termed effusion tumor cells (ETCs), by employing an immunofluorescence‐based CTC‐identification platform (RareCyte) on air‐dried unstained ThinPrep (TP) slides. To facilitate clinical integration, they evaluated different slide processing and storage conditions, hypothesizing that alternative comparable conditions for ETC detection exist.Methods: The authors enumerated ETCs on RareCyte, using morphology and mean fluorescence intensity (MFI) cutoffs of >100 arbitrary units (a.u.) for epithelial cellular adhesion molecule (EpCAM) and <100 a.u. for CD45. They analyzed malignant pleural fluid from three patients under seven processing and/or staining conditions, three patients after short‐term storage under three conditions, and seven samples following long‐term storage at –80°C. MFI values of 4′,6‐diamidino‐2‐phenylindol, cytokeratin, CD45, and EpCAM were compared.Results: ETCs were detected in all conditions. Among the different processing conditions tested, the ethanol‐fixed, unstained TP was most similar to the previously established air‐dried, unstained TP protocol. All smears and Pap‐stained TPs had significantly different marker MFIs from the established condition. After short‐term storage, the established condition showed comparable results, but ethanol‐fixed and Pap‐stained slides showed significant differences. ETCs were detectable after long‐term storage at –80°C in comparable numbers to freshly prepared slides, but most marker MFIs were significantly different.Conclusions: It is possible to detect ETCs under different processing and storage conditions, lending promise to the application of this method in broader settings. Because of decreased immunofluorescence‐signature distinctions between cells, morphology may need to play a larger role.
- 19 February 2024
- Published by Wiley in Cancer Cytopathology
- Vol. 132 (5) , 297-308
Detection of effusion tumor cells under different storage and processing conditions
Background: Circulating tumor cells (CTCs) shed into blood provide prognostic and/or predictive information. Previously, the authors established an assay to detect carcinoma cells from pleural fluid, termed effusion tumor cells (ETCs), by employing an immunofluorescence‐based CTC‐identification platform (RareCyte) on air‐dried unstained ThinPrep (TP) slides. To facilitate clinical integration, they evaluated different slide processing and storage conditions, hypothesizing that alternative comparable conditions for ETC detection exist.Methods: The authors enumerated ETCs on RareCyte, using morphology and mean fluorescence intensity (MFI) cutoffs of >100 arbitrary units (a.u.) for epithelial cellular adhesion molecule (EpCAM) and <100 a.u. for CD45. They analyzed malignant pleural fluid from three patients under seven processing and/or staining conditions, three patients after short‐term storage under three conditions, and seven samples following long‐term storage at –80°C. MFI values of 4′,6‐diamidino‐2‐phenylindol, cytokeratin, CD45, and EpCAM were compared.Results: ETCs were detected in all conditions. Among the different processing conditions tested, the ethanol‐fixed, unstained TP was most similar to the previously established air‐dried, unstained TP protocol. All smears and Pap‐stained TPs had significantly different marker MFIs from the established condition. After short‐term storage, the established condition showed comparable results, but ethanol‐fixed and Pap‐stained slides showed significant differences. ETCs were detectable after long‐term storage at –80°C in comparable numbers to freshly prepared slides, but most marker MFIs were significantly different.Conclusions: It is possible to detect ETCs under different processing and storage conditions, lending promise to the application of this method in broader settings. Because of decreased immunofluorescence‐signature distinctions between cells, morphology may need to play a larger role.
- 17 April 2023
- Published by Wiley in Cancer Cytopathology
- Vol. 131 (8) , 507-515
Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case with strong and diffuse membranous EpCAM staining, making it indistinguishable from carcinoma.Methods: In this study, the authors evaluated all available effusion specimens from patients with malignant mesothelioma, including the above‐mentioned index case, obtained at Stanford Health Care, from 2011 to 2021 (N = 17) as well as control cases (N = 5). Analyses included an immunohistochemistry (IHC) assay for EpCAM and claudin‐4, a multiplexed immunofluorescent (IF) assay for EpCAM, and an RNA in situ hybridization assay targeting EpCAM.Results: The authors detected EpCAM positivity of variable intensity and percentage in four malignant mesothelioma cases (23.5%; although only two showed positivity for the epithelial‐specific IHC marker MOC31 in ≥40% of cells) and claudin‐4 negativity in all cases, with two cases displaying focal and weak claudin‐4 staining in <1% of cells. Multiplexed IF staining on the cases with EpCAM IHC positivity showed strong, membranous EpCAM staining in one of four cases. RNA in situ hybridization also was used to assess the correlation between EpCAM positivity by IHC/IF and RNA expression levels. Strong EpCAM RNA expression was detected in the three malignant mesothelioma cases.Conclusions: The current findings revealed that a subset of epithelioid malignant mesothelioma cases mimic or exhibit the immunophenotypic features of carcinoma when evaluating for EpCAM only. Additional biomarker testing, such as claudin‐4, may help avoid this potential pitfall to yield accurate diagnoses.
- 17 April 2023
- Published by Wiley in Cancer Cytopathology
- Vol. 131 (8) , 507-515
Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case with strong and diffuse membranous EpCAM staining, making it indistinguishable from carcinoma.Methods: In this study, the authors evaluated all available effusion specimens from patients with malignant mesothelioma, including the above‐mentioned index case, obtained at Stanford Health Care, from 2011 to 2021 (N = 17) as well as control cases (N = 5). Analyses included an immunohistochemistry (IHC) assay for EpCAM and claudin‐4, a multiplexed immunofluorescent (IF) assay for EpCAM, and an RNA in situ hybridization assay targeting EpCAM.Results: The authors detected EpCAM positivity of variable intensity and percentage in four malignant mesothelioma cases (23.5%; although only two showed positivity for the epithelial‐specific IHC marker MOC31 in ≥40% of cells) and claudin‐4 negativity in all cases, with two cases displaying focal and weak claudin‐4 staining in <1% of cells. Multiplexed IF staining on the cases with EpCAM IHC positivity showed strong, membranous EpCAM staining in one of four cases. RNA in situ hybridization also was used to assess the correlation between EpCAM positivity by IHC/IF and RNA expression levels. Strong EpCAM RNA expression was detected in the three malignant mesothelioma cases.Conclusions: The current findings revealed that a subset of epithelioid malignant mesothelioma cases mimic or exhibit the immunophenotypic features of carcinoma when evaluating for EpCAM only. Additional biomarker testing, such as claudin‐4, may help avoid this potential pitfall to yield accurate diagnoses.
- 19 October 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (6) , S16-S17
Science, Medicine, and Cytology: A Pilot Program of the ASC Diversity Equity and Inclusion (DEI) Committee
- 19 October 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (6) , S16-S17
Science, Medicine, and Cytology: A Pilot Program of the ASC Diversity Equity and Inclusion (DEI) Committee
- 22 June 2022
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (10) , 771-782
Immunofluorescent and molecular characterization of effusion tumor cells reveal cancer site‐of‐origin and disease‐driving mutations
Background: Effective cancer treatment relies on precision diagnostics. In cytology, an accurate diagnosis facilitates the determination of proper therapeutics for patients with cancer. Previously, the authors developed a multiplexed immunofluorescent panel to detect epithelial malignancies from pleural effusion specimens. Their assay reliably distinguished effusion tumor cells (ETCs) from nonmalignant cells; however, it lacked the capacity to reveal specific cancer origin information. Furthermore, DNA profiling of ETCs revealed some, but not all, cancer‐driver mutations.Methods: The authors developed a new multiplex immunofluorescent panel that detected both malignancy and pulmonary origin by incorporating the thyroid transcription factor‐1 (TTF‐1) biomarker. Evaluation for TTF‐1–positive ETCs (T‐ETCs) was performed on 12 patient samples. T‐ETCs and parallel ETCs from selected patients were collected and subjected to DNA profiling to identify pathogenic mutations. All samples were obtained with Institutional Review Board approval.Results: Malignancy was detected in all samples. T‐ETCs were identified in 9 of 10 patients who had clinically reported TTF‐1 positivity (90% sensitivity and 100% specificity). Furthermore, DNA profiling of as few as five T‐ETCs identified pathogenic mutations with equal or greater sensitivity compared with profiling of ETCs, both of which showed high concordance with clinical findings.Conclusions: The findings suggest that the immunofluorescent and molecular characterization of tumor cells from pleural effusion specimens can provide reliable diagnostic information, even with very few cells. The integration of site‐specific biomarkers like TTF‐1 into ETC analysis may facilitate better refined diagnosis and improve patient care.
- 22 June 2022
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (10) , 771-782
Immunofluorescent and molecular characterization of effusion tumor cells reveal cancer site‐of‐origin and disease‐driving mutations
Background: Effective cancer treatment relies on precision diagnostics. In cytology, an accurate diagnosis facilitates the determination of proper therapeutics for patients with cancer. Previously, the authors developed a multiplexed immunofluorescent panel to detect epithelial malignancies from pleural effusion specimens. Their assay reliably distinguished effusion tumor cells (ETCs) from nonmalignant cells; however, it lacked the capacity to reveal specific cancer origin information. Furthermore, DNA profiling of ETCs revealed some, but not all, cancer‐driver mutations.Methods: The authors developed a new multiplex immunofluorescent panel that detected both malignancy and pulmonary origin by incorporating the thyroid transcription factor‐1 (TTF‐1) biomarker. Evaluation for TTF‐1–positive ETCs (T‐ETCs) was performed on 12 patient samples. T‐ETCs and parallel ETCs from selected patients were collected and subjected to DNA profiling to identify pathogenic mutations. All samples were obtained with Institutional Review Board approval.Results: Malignancy was detected in all samples. T‐ETCs were identified in 9 of 10 patients who had clinically reported TTF‐1 positivity (90% sensitivity and 100% specificity). Furthermore, DNA profiling of as few as five T‐ETCs identified pathogenic mutations with equal or greater sensitivity compared with profiling of ETCs, both of which showed high concordance with clinical findings.Conclusions: The findings suggest that the immunofluorescent and molecular characterization of tumor cells from pleural effusion specimens can provide reliable diagnostic information, even with very few cells. The integration of site‐specific biomarkers like TTF‐1 into ETC analysis may facilitate better refined diagnosis and improve patient care.
- 25 June 2021
- Published by Wiley in Cancer Cytopathology
- Vol. 129 (11) , 893-906
Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens
Background Cancer is a leading cause of death worldwide, and patients may have advanced disease when diagnosed. Targeted therapies guided by molecular subtyping of cancer can benefit patients significantly. Pleural effusions are frequently observed in patients with metastatic cancer and are routinely removed for therapeutic purposes; however, effusion specimens have not been recognized as typical substrates for clinical molecular testing because of frequent low tumor cellularity. Methods Excess remnant pleural effusion samples (N = 25) from 21 patients with and without suspected malignancy were collected at Stanford Health Care between December 2019 and November 2020. Samples were processed into ThinPrep slides and underwent novel effusion tumor cell (ETC) analysis. The ETC results were compared with the original clinical diagnoses for accuracy. A subset of confirmed ETCs was further isolated and processed for molecular profiling to identify cancer driver mutations. All samples were obtained with Institutional Review Board approval. Results The authors established novel quantitative standards to identify ETCs and detected epithelial malignancy with 89.5% sensitivity and 100% specificity in the pleural effusion samples. Molecular profiling of confirmed ETCs (pools of 5 cells evaluated) revealed key pathogenic mutations consistent with clinical molecular findings. Conclusions In this study, the authors developed a novel ETC-testing assay that detected epithelial malignancies in pleural effusions with high sensitivity and specificity. Molecular profiling of 5 ETCs showed promising concordance with the clinical molecular findings. To promote cancer subtyping and guide treatment, this ETC-testing assay will need to be validated in larger patient cohorts to facilitate integration into cytologic workflow.
- 25 June 2021
- Published by Wiley in Cancer Cytopathology
- Vol. 129 (11) , 893-906
Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens
Background Cancer is a leading cause of death worldwide, and patients may have advanced disease when diagnosed. Targeted therapies guided by molecular subtyping of cancer can benefit patients significantly. Pleural effusions are frequently observed in patients with metastatic cancer and are routinely removed for therapeutic purposes; however, effusion specimens have not been recognized as typical substrates for clinical molecular testing because of frequent low tumor cellularity. Methods Excess remnant pleural effusion samples (N = 25) from 21 patients with and without suspected malignancy were collected at Stanford Health Care between December 2019 and November 2020. Samples were processed into ThinPrep slides and underwent novel effusion tumor cell (ETC) analysis. The ETC results were compared with the original clinical diagnoses for accuracy. A subset of confirmed ETCs was further isolated and processed for molecular profiling to identify cancer driver mutations. All samples were obtained with Institutional Review Board approval. Results The authors established novel quantitative standards to identify ETCs and detected epithelial malignancy with 89.5% sensitivity and 100% specificity in the pleural effusion samples. Molecular profiling of confirmed ETCs (pools of 5 cells evaluated) revealed key pathogenic mutations consistent with clinical molecular findings. Conclusions In this study, the authors developed a novel ETC-testing assay that detected epithelial malignancies in pleural effusions with high sensitivity and specificity. Molecular profiling of 5 ETCs showed promising concordance with the clinical molecular findings. To promote cancer subtyping and guide treatment, this ETC-testing assay will need to be validated in larger patient cohorts to facilitate integration into cytologic workflow.
- Open Access
- 22 April 2020
- Published by Wiley in Cancer Cytopathology
- Vol. 128 (8) , 518-519
Multiplexed fluorescence in situ hybridization–based detection of circulating tumor cells: A novel liquid‐based technology to facilitate accurate and early identification of non–small cell lung cancer patients
Multiplexed fluorescence in situ hybridization–based circulating tumor cell (CTC) technology detects cytogenetic abnormalities in patients who are at risk for non–small cell lung cancer with high accuracy. Combined with low‐dose computed tomography, this CTC technology can efficiently rule out malignancy in at‐risk patients with benign pulmonary nodules.
- 22 April 2020
- Published by Wiley in Cancer Cytopathology
- Vol. 128 (8) , 518-519
Open AccessMultiplexed fluorescence in situ hybridization–based detection of circulating tumor cells: A novel liquid‐based technology to facilitate accurate and early identification of non–small cell lung cancer patients
Multiplexed fluorescence in situ hybridization–based circulating tumor cell (CTC) technology detects cytogenetic abnormalities in patients who are at risk for non–small cell lung cancer with high accuracy. Combined with low‐dose computed tomography, this CTC technology can efficiently rule out malignancy in at‐risk patients with benign pulmonary nodules.